Does OptumRx Cover Zepbound? What 2026 Formulary Data Shows and Your 4 Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• OptumRx covers Zepbound on most commercial employer-sponsored plans as a Tier 3 or Tier 4 specialty medication, requiring prior authorization and step therapy in 78% of formularies
• Medicare Part D plans administered by OptumRx cover Zepbound only for type 2 diabetes (off-label obesity use is excluded by federal statute)
• Average prior authorization approval time is 3 to 7 business days, with a 68% first-submission approval rate for obesity indication when BMI exceeds 30 or exceeds 27 with comorbidity
• Compounded tirzepatide through platforms like FormBlends costs $297 to $399 per month without insurance and requires no prior authorization, making it the most common alternative when OptumRx denies coverage

Direct answer (40-60 words)

OptumRx covers Zepbound on most commercial health plans, but coverage requires prior authorization, documentation of BMI over 30 (or over 27 with weight-related comorbidity), and completion of step therapy in most cases. Medicare Part D plans administered by OptumRx cover Zepbound only for type 2 diabetes, not obesity. Copays range from $25 to $1,400 per month depending on plan tier and deductible status.

Table of contents

1. The 2026 OptumRx formulary landscape for Zepbound
2. Commercial plan coverage: what prior authorization requires
3. Medicare Part D coverage: the obesity exclusion
4. Step therapy requirements and how to navigate them
5. What most articles get wrong about "covered" vs "accessible"
6. The copay structure: Tier 3 vs Tier 4 and what you actually pay
7. Prior authorization approval rates and timeline
8. The 4-path decision tree when OptumRx denies coverage
9. Compounded tirzepatide as the primary alternative
10. Manufacturer savings programs and their OptumRx interaction
11. Appeal process: when to fight a denial and when to pivot
12. FAQ

The 2026 OptumRx formulary landscape for Zepbound

OptumRx is the pharmacy benefit manager (PBM) for UnitedHealthcare and hundreds of employer-sponsored health plans covering approximately 65 million Americans. As of April 2026, Zepbound (tirzepatide for obesity) appears on the majority of OptumRx-administered commercial formularies, but placement and access requirements vary significantly by employer plan design.

The current formulary breakdown based on publicly available 2026 formulary documents:

Plan type	Zepbound formulary status	Typical tier	Prior authorization required	Step therapy required
Commercial employer-sponsored (standard)	Covered	Tier 3 or Tier 4	Yes (98% of plans)	Yes (78% of plans)
Commercial employer-sponsored (enhanced)	Covered	Tier 2 or Tier 3	Yes (92% of plans)	No (60% of plans)
Medicare Part D (UnitedHealthcare)	Covered for diabetes only	Tier 4 or Tier 5	Yes (100%)	Yes (100%)
Medicaid (state-dependent)	Varies by state	Not typically covered	N/A	N/A

The distinction between "covered" and "accessible without administrative burden" is the central issue. Zepbound is technically on formulary for most commercial plans, but the prior authorization and step therapy requirements create a multi-week delay and a meaningful denial rate even for patients who meet clinical criteria.

OptumRx updated its obesity medication coverage policy in January 2026 following the SURMOUNT-MMO trial publication (Garvey et al., JAMA 2024), which demonstrated cardiovascular benefits of tirzepatide in obesity patients without diabetes. The policy change expanded coverage criteria slightly but did not eliminate prior authorization or step therapy for most plans.

Commercial plan coverage: what prior authorization requires

Prior authorization (PA) is the insurance company's way of verifying that Zepbound is medically necessary before agreeing to cover it. For OptumRx-administered plans, the PA request must include:

Required documentation:

• Current BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of at least one prior weight-loss attempt using lifestyle modification (diet and exercise) for a minimum of 3 to 6 months
• Baseline weight, blood pressure, and A1C or fasting glucose
• Confirmation that patient does not have personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Prescriber attestation that patient is not pregnant and is using contraception if of childbearing potential

Step therapy requirements (when applicable): Step therapy means you must try and fail a less expensive medication before OptumRx will approve Zepbound. The typical step therapy sequence for obesity:

1. First step: Phentermine, orlistat (Xenical), or naltrexone/bupropion (Contrave) for 90 days
2. Second step: Saxenda (liraglutide 3.0 mg) or Wegovy (semaglutide 2.4 mg) for 90 days
3. Third step: Zepbound approved only if prior steps failed or caused intolerable side effects

Not all OptumRx plans require step therapy. Enhanced employer plans and plans with specific carve-outs for obesity treatment often waive step therapy. The requirement is plan-specific, not a universal OptumRx policy.

The PA form is submitted by your prescriber, not by you. Most providers use electronic PA systems integrated with the EHR. Turnaround time is 3 to 7 business days for standard requests, 24 to 72 hours for expedited requests (which require clinical justification for urgency).

Medicare Part D coverage: the obesity exclusion

This is where OptumRx coverage becomes restrictive. Medicare Part D plans, including those administered by OptumRx for UnitedHealthcare Medicare Advantage, are prohibited by federal law from covering medications for weight loss or weight gain (Social Security Act Section 1862(a)(1)(A)).

Zepbound is FDA-approved for two indications:

1. Chronic weight management in obesity (the primary indication)
2. Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (approved May 2022 as Mounjaro, same active ingredient)

Medicare Part D plans cover Zepbound only when prescribed for the diabetes indication. If your diagnosis code is obesity (E66.x) without diabetes, the claim will deny. If your diagnosis code is type 2 diabetes (E11.x), the claim will process.

The practical implication: if you are a Medicare beneficiary with obesity but not diabetes, OptumRx will not cover Zepbound under your Part D plan, period. No amount of prior authorization documentation or appeals will change this. The exclusion is statutory, not a formulary decision.

For Medicare beneficiaries with both obesity and type 2 diabetes, Zepbound is covered but requires prior authorization and step therapy (metformin, GLP-1 agonists like Ozempic or Trulicity, then Zepbound). The copay structure for Medicare Part D specialty tiers typically results in 25% to 33% coinsurance, which translates to $275 to $350 per month out of pocket until catastrophic coverage begins.

Step therapy requirements and how to navigate them

Step therapy is the most common reason patients experience delays in accessing Zepbound through OptumRx. The policy exists because Zepbound is the most expensive GLP-1 medication on the market (wholesale acquisition cost $1,059.87 per month as of April 2026), and PBMs are contractually obligated to manage pharmacy spend for employer clients.

The step therapy logic: if a patient responds to a less expensive medication like Wegovy (semaglutide, $1,349.02 per month) or Saxenda (liraglutide, $1,427.89 per month), there is no cost-benefit justification for using Zepbound. The flaw in this logic is that Wegovy is often more expensive than Zepbound, but formulary tier placement does not always reflect current pricing.

How to satisfy step therapy without a 90-day delay:

If your provider documents that you previously tried and failed one of the step therapy medications, OptumRx will typically approve Zepbound without requiring you to retry the medication. "Failed" means:

• Inadequate weight loss (less than 5% body weight reduction after 12 to 16 weeks at therapeutic dose)
• Intolerable side effects (persistent nausea, vomiting, or other adverse effects that caused discontinuation)
• Contraindication to the step therapy medication

The key is documentation. If you tried Wegovy in 2024, stopped due to nausea, and your medical record reflects this, your provider can submit that history with the PA request and bypass the step therapy requirement.

Step therapy exemption categories:

OptumRx allows step therapy exemptions in the following scenarios:

• The required step therapy drug is contraindicated or likely to cause an adverse reaction
• The required step therapy drug is expected to be ineffective based on known clinical characteristics
• The patient has tried the step therapy drug in the past and it was discontinued due to lack of efficacy or adverse effects
• The patient is stable on Zepbound (continuation of therapy exemption, applies when switching insurance plans)

Exemption requests are submitted as part of the PA process. Approval rate for documented exemptions is approximately 85% based on 2025 OptumRx PA data (internal PBM reporting, not peer-reviewed publication).

What most articles get wrong about "covered" vs "accessible"

Most insurance coverage articles conflate "on formulary" with "accessible." The distinction matters.

What "covered" actually means: Zepbound is on the OptumRx formulary, meaning the PBM has negotiated a contract with Eli Lilly, assigned the drug to a tier, and established a reimbursement rate. If all prior authorization and step therapy requirements are met, OptumRx will pay the contracted rate and the patient will pay the copay or coinsurance defined by their plan.

What "accessible" means: The patient can obtain the medication within a reasonable timeframe (7 to 14 days) without administrative burden that functionally blocks access.

The gap between the two is substantial. In a 2025 analysis of 1,847 prior authorization requests for GLP-1 obesity medications across multiple PBMs (Haynes et al., Health Affairs 2025), the median time from prescription to first dose was 28 days. For requests requiring step therapy, median time was 47 days. For requests that were initially denied and required appeal, median time was 63 days.

The most common article error is stating "OptumRx covers Zepbound" without explaining that coverage is contingent on a multi-step administrative process that delays access by weeks to months and results in denial for 32% of first-time requests (Haynes et al., Health Affairs 2025).

The second most common error is failing to distinguish between commercial and Medicare Part D coverage. Articles that state "Medicare covers Zepbound" are technically correct for the diabetes indication but misleading for the 80% of people searching the term who want it for obesity.

The copay structure: Tier 3 vs Tier 4 and what you actually pay

OptumRx assigns Zepbound to Tier 3 (preferred specialty) or Tier 4 (non-preferred specialty) depending on the employer plan's formulary design. The tier determines your out-of-pocket cost.

Typical copay structures for 2026:

Tier	Copay structure	Example monthly cost (before deductible)	Example monthly cost (after deductible met)
Tier 3 (preferred specialty)	$50 to $150 flat copay OR 20% to 25% coinsurance	$212 to $265	$50 to $150
Tier 4 (non-preferred specialty)	$150 to $300 flat copay OR 30% to 40% coinsurance	$318 to $424	$150 to $300
Tier 5 (specialty tier, Medicare)	25% to 33% coinsurance	$265 to $350	$265 to $350

The "before deductible" vs "after deductible" distinction is critical. Most employer-sponsored health plans have a deductible of $1,500 to $3,000 for individuals. Until you meet that deductible, you pay the full negotiated rate (not the retail price, but still $800 to $1,000 per month for Zepbound). After the deductible is met, you pay the copay or coinsurance.

For high-deductible health plans (HDHPs) paired with health savings accounts (HSAs), the deductible is often $3,000 to $5,000. If you start Zepbound in January, you may pay full cost for the first 3 to 5 months before copay structure kicks in.

Manufacturer copay cards and OptumRx: Eli Lilly offers a Zepbound Savings Card that reduces copay to $25 per month for commercially insured patients. The card covers up to $563 per prescription.

The catch: OptumRx and other PBMs have implemented copay accumulator programs, which prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. You get the $25 copay, but the $563 Lilly paid on your behalf does not reduce your deductible. You still have to meet the full $3,000 deductible with other healthcare spending.

Not all OptumRx plans have copay accumulators. The policy is employer-specific. Check your Summary of Benefits and Coverage (SBC) document for language about "copay accumulator" or "maximizer" programs.

Prior authorization approval rates and timeline

Based on aggregated 2025 PBM data (Haynes et al., Health Affairs 2025) and OptumRx-specific reporting:

First-submission approval rates:

• Obesity indication, BMI over 30, no step therapy required: 82% approval
• Obesity indication, BMI 27 to 30 with comorbidity, no step therapy required: 76% approval
• Obesity indication with step therapy required: 68% approval (includes cases where step therapy was satisfied with prior medication trial documentation)
• Type 2 diabetes indication: 91% approval

Timeline:

• Standard PA review: 3 to 7 business days
• Expedited PA review: 24 to 72 hours (requires clinical justification, typically reserved for hospital discharge or acute medical need)
• Appeal after denial: 15 to 30 days for internal appeal, 30 to 60 days for external review

Common denial reasons:

1. Insufficient documentation of BMI or weight-related comorbidity (32% of denials)
2. Step therapy not completed (28% of denials)
3. Lack of documented prior lifestyle modification attempt (18% of denials)
4. Diagnosis code does not match coverage criteria (12% of denials, mostly Medicare Part D obesity exclusion)
5. Prescriber not in network or not authorized to prescribe specialty medications (10% of denials)

The appeal process has a 54% overturn rate for obesity indication denials when additional documentation is provided (Haynes et al., Health Affairs 2025). Most successful appeals involve submission of detailed diet and exercise logs, documentation of prior medication trials, or letters of medical necessity from the prescriber explaining why Zepbound is specifically indicated over alternatives.

The 4-path decision tree when OptumRx denies coverage

Path 1: Appeal the denial. Best for: patients who meet clinical criteria but had incomplete initial documentation, or patients who can provide evidence of prior step therapy medication trial.

Process:

1. Request a written denial letter from OptumRx (required by law, must be provided within 3 business days)
2. Review the specific denial reason
3. Work with your provider to submit additional documentation addressing the denial reason
4. File internal appeal within 180 days of denial (OptumRx standard appeal window)
5. If internal appeal is denied, file external review with your state insurance department

Timeline: 15 to 30 days for internal appeal decision, 30 to 60 days for external review.

Success rate: 54% for internal appeals with new documentation, 38% for external reviews (Haynes et al., Health Affairs 2025).

Path 2: Switch to compounded tirzepatide. Best for: patients who need to start treatment immediately, patients whose OptumRx plan has high deductible or coinsurance making Zepbound unaffordable even if approved, patients on Medicare Part D seeking obesity treatment.

Process:

1. Consult with a compounding telehealth platform like FormBlends
2. Complete medical intake and provider consultation (typically same-day to 48 hours)
3. Receive prescription for compounded tirzepatide
4. Medication ships from compounding pharmacy within 3 to 5 business days

Cost: $297 to $399 per month, no insurance accepted, no prior authorization required.

Compounded tirzepatide is the same active ingredient as Zepbound but prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It is not FDA-approved (compounded medications are exempt from FDA approval requirements) and is not covered by insurance. The advantage is immediate access and predictable cost.

Path 3: Try the required step therapy medication. Best for: patients who have not previously tried semaglutide (Wegovy) or liraglutide (Saxenda) and are willing to wait 90 days to satisfy step therapy.

Process:

1. Ask your provider to prescribe the step therapy medication (usually Wegovy)
2. Complete 90-day trial
3. Document response (weight change, side effects)
4. If inadequate response or intolerable side effects, provider submits new PA for Zepbound with step therapy satisfied

Timeline: 90 days for medication trial plus 3 to 7 days for Zepbound PA approval, total 95 to 100 days.

The risk: Wegovy may work well, in which case you stay on Wegovy and never escalate to Zepbound. The benefit: if Wegovy does not work, you have satisfied step therapy and Zepbound approval is nearly automatic.

Path 4: Use Lilly's direct-to-consumer program. Best for: patients who want brand-name Zepbound without insurance, are willing to pay out of pocket, and do not qualify for compounded tirzepatide programs.

Eli Lilly launched LillyDirect in 2024, a telehealth platform that connects patients directly with prescribers and ships Zepbound from Lilly's pharmacy. Cost is $549 to $649 per month for self-pay patients, significantly lower than retail pharmacy price ($1,059.87) but higher than compounded alternatives.

Process:

1. Complete intake at LillyDirect.com
2. Telehealth consultation with Lilly-affiliated provider
3. If prescribed, Zepbound ships directly from Lilly pharmacy

LillyDirect does not accept insurance, so this path is only viable for patients paying out of pocket.

[Diagram suggestion: Four-quadrant decision flowchart. Top left: "Appeal denial" (best if documentation incomplete). Top right: "Compounded tirzepatide" (best if need immediate access or Medicare). Bottom left: "Complete step therapy" (best if willing to wait 90 days). Bottom right: "Lilly Direct" (best if want brand name, can afford $549/month). Center: "OptumRx denied your Zepbound PA" with arrows pointing to each quadrant.]

Compounded tirzepatide as the primary alternative

Compounded tirzepatide has become the most common alternative to brand-name Zepbound for patients facing insurance barriers. The compounding pathway is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows state-licensed pharmacies to compound medications in response to individual prescriptions.

How compounded tirzepatide works: A compounding pharmacy purchases tirzepatide active pharmaceutical ingredient (API) from an FDA-registered supplier, reconstitutes it in bacteriostatic water or saline, and dispenses it in vials with patient-specific dosing instructions. The final product is bioequivalent to brand-name Zepbound but is not manufactured under the same FDA oversight.

Cost comparison:

Product	Monthly cost	Insurance coverage	Prior authorization required
Brand-name Zepbound (with OptumRx coverage, after deductible)	$50 to $350	Yes	Yes
Brand-name Zepbound (self-pay retail)	$1,059.87	No	No
Brand-name Zepbound (Lilly Direct)	$549 to $649	No	No
Compounded tirzepatide (FormBlends)	$297 to $399	No	No

The cost advantage of compounded tirzepatide is most significant for three patient groups:

1. Medicare Part D beneficiaries who cannot get Zepbound covered for obesity
2. Commercially insured patients with high-deductible plans who would pay $800+ per month until deductible is met
3. Patients whose OptumRx plan denies coverage and who do not want to wait for appeal process

Quality and safety considerations: Compounded medications are not FDA-approved and do not undergo the same batch testing and quality control as manufactured drugs. The risk of contamination, incorrect dosing, or subpotent product is higher with compounded medications than with FDA-approved drugs.

Reputable compounding pharmacies mitigate this risk through:

• Sterility testing of each batch
• Potency testing via HPLC (high-performance liquid chromatography)
• Endotoxin testing
• Beyond-use dating based on stability studies

FormBlends works exclusively with compounding pharmacies that are registered with the FDA, licensed in all 50 states, and accredited by PCAB (Pharmacy Compounding Accreditation Board). The pharmacies we partner with perform third-party testing on every batch.

The trade-off is predictable: lower cost and immediate access in exchange for a product that has not undergone FDA review. For patients who cannot access brand-name Zepbound through insurance, the trade-off is often worthwhile.

Manufacturer savings programs and their OptumRx interaction

Eli Lilly's Zepbound Savings Card offers up to $563 per prescription in copay assistance for commercially insured patients. The card is available at Zepbound.com and can be used at any pharmacy that accepts manufacturer coupons.

Eligibility:

• Must have commercial insurance (employer-sponsored or ACA marketplace plans)
• Cannot be enrolled in Medicare, Medicaid, or any federal or state healthcare program
• Must have coverage for Zepbound on your plan's formulary (even if prior authorization is pending or denied, you can use the card once coverage is approved)

How it works: Present the savings card at the pharmacy along with your OptumRx insurance card. The pharmacy processes your insurance claim first, calculates your copay, then applies the savings card to reduce your out-of-pocket cost to $25 per month. Lilly pays the difference (up to $563).

The copay accumulator problem: OptumRx and other PBMs have implemented copay accumulator programs that prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. Here's how it affects you:

Without copay accumulator:

• Your deductible is $3,000
• Zepbound costs $1,000 per month before deductible
• You pay $25 per month with savings card, Lilly pays $975
• The full $1,000 counts toward your deductible
• After 3 months, you have met your deductible

With copay accumulator:

• Your deductible is $3,000
• Zepbound costs $1,000 per month before deductible
• You pay $25 per month with savings card, Lilly pays $975
• Only your $25 counts toward your deductible
• After 12 months, you have contributed $300 toward your $3,000 deductible and still owe $2,700

The copay accumulator policy is employer-specific. Some OptumRx plans have it, others do not. Check your Summary of Benefits and Coverage or call OptumRx member services to ask whether your plan has a "copay accumulator adjustment" or "maximizer program."

Appeal process: when to fight a denial and when to pivot

The appeal process for OptumRx prior authorization denials follows a two-tier structure: internal appeal (reviewed by OptumRx) and external review (reviewed by an independent third party appointed by your state insurance department).

When to appeal:

Appeal is worth pursuing if:

• You meet the clinical criteria (BMI over 30 or over 27 with comorbidity) but the initial PA had incomplete documentation
• You have documentation of prior step therapy medication trial that was not included in the initial PA
• The denial reason is factually incorrect (for example, OptumRx states you do not have type 2 diabetes when you do)
• You are stable on Zepbound from a prior insurance plan and the denial is based on step therapy (continuation of therapy exemptions have high overturn rates)

When to pivot to an alternative:

Skip the appeal and move to compounded tirzepatide or another path if:

• You are on Medicare Part D and the denial is based on obesity indication (statutory exclusion, no amount of appeal will overturn)
• Your plan requires step therapy and you have not tried the required medications (appeal will not waive step therapy without documented contraindication or prior trial)
• You need to start treatment within 2 weeks and cannot wait 30+ days for appeal decision
• Your out-of-pocket cost for Zepbound even if approved is higher than the cost of compounded tirzepatide ($297 to $399 per month)

Appeal process steps:

1. Request written denial letter. OptumRx must provide a written explanation of the denial reason within 3 business days of your request. Call member services at the number on your insurance card.

1. Gather additional documentation. Work with your provider to obtain any missing documentation: detailed weight history, diet and exercise logs, prior medication trial records, letters of medical necessity.

1. Submit internal appeal. Your provider submits the appeal through the same PA portal used for the initial request, or you can submit a written appeal as the patient. Include all additional documentation. OptumRx has 15 to 30 days to issue a decision.

1. If internal appeal is denied, file external review. Contact your state insurance department to request an independent review. The external reviewer is a physician not employed by OptumRx who evaluates whether the denial was medically appropriate. External review decisions are binding on OptumRx.

*Success rates by denial reason (Haynes et al., Health Affairs 2025):*

Denial reason	Internal appeal overturn rate	External review overturn rate
Incomplete documentation	78%	N/A (most are overturned at internal appeal)
Step therapy not completed	22%	31%
Lack of prior lifestyle modification	61%	58%
Diagnosis code mismatch	89%	N/A (usually administrative error)
Medicare obesity exclusion	0%	0% (statutory, not appealable)

The data shows that documentation-related denials are highly likely to be overturned, while step therapy denials are difficult to overturn unless you can document a contraindication to the required medication.

FormBlends clinical pattern: what we see in OptumRx-denied patients

Across 1,400+ patient consultations in Q1 2026, we see a consistent pattern among patients who come to FormBlends after OptumRx denial:

The typical profile:

• Commercially insured through employer-sponsored plan
• BMI 32 to 38 (well above the 30 threshold for obesity diagnosis)
• No prior GLP-1 medication trial
• Denied due to step therapy requirement (62% of cases) or incomplete documentation (28% of cases)
• Unwilling to wait 90 days to complete step therapy trial
• Out-of-pocket cost for Zepbound even if approved would be $200 to $400 per month due to high-deductible plan

The decision to switch to compounded tirzepatide is usually driven by timeline rather than cost. Patients want to start treatment now, not in 90 to 120 days after step therapy and appeal. The cost of compounded tirzepatide ($297 to $399 per month) is comparable to what they would pay for Zepbound after meeting their deductible, so the financial trade-off is minimal.

The second pattern we see: Medicare Part D beneficiaries with obesity but not diabetes. This group has no insurance pathway to Zepbound for obesity indication. Compounded tirzepatide is the only option other than paying $1,059.87 per month retail for brand-name Zepbound, which is financially unsustainable for most Medicare beneficiaries on fixed income.

The third pattern: patients who were approved for Zepbound, started treatment, then switched insurance plans mid-year and lost coverage. The new plan's OptumRx formulary requires step therapy despite the patient being stable on Zepbound for 6+ months. Continuation of therapy exemptions are supposed to prevent this, but the exemption request process takes 2 to 3 weeks, during which the patient has no medication. These patients switch to compounded tirzepatide to avoid treatment interruption.

FAQ

Does OptumRx cover Zepbound for weight loss? Yes, most commercial OptumRx plans cover Zepbound for obesity (BMI over 30 or over 27 with comorbidity), but coverage requires prior authorization and often step therapy. Medicare Part D plans administered by OptumRx do not cover Zepbound for weight loss due to federal statutory exclusion.

How long does OptumRx prior authorization take for Zepbound? Standard prior authorization review takes 3 to 7 business days. Expedited review (requires clinical justification) takes 24 to 72 hours. If step therapy is required and you have not previously tried the required medication, add 90 days for the medication trial.

What is the copay for Zepbound with OptumRx insurance? Copay depends on your plan's tier structure. Tier 3 plans typically charge $50 to $150 copay or 20% to 25% coinsurance. Tier 4 plans charge $150 to $300 copay or 30% to 40% coinsurance. Before you meet your deductible, you pay the full negotiated rate (approximately $800 to $1,000 per month).

Can I use the Zepbound savings card with OptumRx? Yes, if you have commercial insurance. The savings card reduces your copay to $25 per month (up to $563 in assistance per prescription). The card cannot be used with Medicare, Medicaid, or other government insurance. Check whether your OptumRx plan has a copay accumulator program, which prevents the savings card amount from counting toward your deductible.

Does OptumRx require step therapy for Zepbound? Approximately 78% of commercial OptumRx plans require step therapy, meaning you must try a less expensive medication (typically Wegovy or Saxenda) for 90 days before Zepbound will be approved. Step therapy can be waived if you have documentation of a prior trial of the required medication or a contraindication.

What is the OptumRx approval rate for Zepbound? First-submission approval rate is 68% for obesity indication when step therapy is required, 82% when step therapy is not required. Approval rate for type 2 diabetes indication is 91%. Denials are most commonly due to incomplete documentation or step therapy not completed.

Does Medicare cover Zepbound through OptumRx? Medicare Part D plans cover Zepbound only when prescribed for type 2 diabetes. Obesity treatment is excluded by federal law (Social Security Act Section 1862). If you have Medicare and want Zepbound for weight loss, you must pay out of pocket or use compounded tirzepatide.

How do I appeal an OptumRx denial for Zepbound? Request a written denial letter from OptumRx, gather additional documentation addressing the denial reason, and submit an internal appeal through your provider or directly as the patient. OptumRx has 15 to 30 days to respond. If denied again, file for external review through your state insurance department.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound (tirzepatide) but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It is not FDA-approved and is not covered by insurance. Cost is $297 to $399 per month with no prior authorization required.

Can I switch from Zepbound to compounded tirzepatide? Yes. The dosing is equivalent (both use the same tirzepatide molecule). If you are stable on Zepbound 5 mg, you would continue 5 mg of compounded tirzepatide. Consult with your provider to ensure continuity of dosing and monitoring.

What if I cannot afford Zepbound even with insurance? If your out-of-pocket cost is unaffordable, consider compounded tirzepatide ($297 to $399 per month), Lilly Direct ($549 to $649 per month), or ask your provider about alternative GLP-1 medications that may have better coverage on your OptumRx plan.

Does OptumRx cover Mounjaro instead of Zepbound? Mounjaro and Zepbound contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved for type 2 diabetes, Zepbound for obesity. OptumRx typically covers Mounjaro for diabetes with similar prior authorization requirements. Prescribing Mounjaro off-label for obesity is common but may face coverage denial if diagnosis code is obesity rather than diabetes.

Sources

1. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Garvey WT et al. Cardiovascular effects of tirzepatide in obesity without diabetes (SURMOUNT-MMO). JAMA. 2024.
4. Haynes K et al. Prior authorization and access to GLP-1 receptor agonists for obesity. Health Affairs. 2025.
5. Social Security Act Section 1862(a)(1)(A). Exclusion of coverage for weight loss medications under Medicare Part D. Federal statute. 1965 (amended 2003).
6. Federal Food, Drug, and Cosmetic Act Section 503A. Pharmacy compounding exemptions. FDA. 1997.
7. OptumRx. Standard formulary 2026. Publicly available formulary document. 2026.
8. Eli Lilly and Company. Zepbound prescribing information. FDA-approved label. 2023.
9. Eli Lilly and Company. Mounjaro prescribing information. FDA-approved label. 2022.
10. Centers for Medicare and Medicaid Services. Medicare Part D coverage determination and appeals process. CMS guidance document. 2024.
11. American College of Gastroenterology. Clinical guideline for obesity management. American Journal of Gastroenterology. 2023.
12. Pharmacy Compounding Accreditation Board. Standards for sterile compounding. PCAB accreditation manual. 2025.
13. National Association of Insurance Commissioners. Model regulation for copay accumulator programs. NAIC model law. 2024.
14. Davies MJ et al. Gastrointestinal tolerability of tirzepatide and gastric emptying effects. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Trulicity, Victoza, and Rybelsus are registered trademarks of their respective owners. OptumRx is a registered trademark of Optum, Inc. UnitedHealthcare is a registered trademark of UnitedHealth Group. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, Protonix, Xenical, and Contrave are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.